These studies shed light on the scientific controversy of whether activation of the Wnt/β-catenin pathway induces human stem cell pluripotency or differentiation.

“MERCURIUS™ Total DRUG-seq represents a new frontier in transcriptome-scale compound screening,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “We are empowering scientists to capture the full complexity of transcriptional responses—at a massive scale and with minimal cost. This product opens the door to discovering new biology, new targets, and new drugs faster than ever before.”

The new 133,500-square-foot headquarters at 12001 Exit 5 Parkway will house an advanced pharmacy featuring category III, 503A/503B compounding capabilities alongside integrated telemedicine services for peptide therapy management and prescription fulfillment.

Merck KGaA, Darmstadt, Germany, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib in TGCT.

Eisai plans to launch this medicine in China in the second quarter of fiscal year 2025.

Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world’s first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway.